By Kerri Hatt
NEW YORK – Empire BlueCross BlueShield and Mount Sinai Health System announced an agreement focused on new models of care to lower health care costs and increase value for New Yorkers. The multi-year agreement includes three new models of care, which provide members of the Empire with access to Mount Sinai’s emergency triage, treatment and transportation (ET3) programs and community paramedic programs.
These models of care provide EMS with greater flexibility to meet the emergency health care needs of Empire members, which may result in on-site treatment with or without telehealth where appropriate. With the ET3 model, members who call 911 and whose Mount Sinai is dispatched will be able to receive, when medically appropriate, home care instead of going to the emergency room. Likewise, through the community paramedic model, members who call a Mount Sinai doctor for care can choose to have a paramedic dispatched to their home to potentially avoid a trip to the hospital. âBoth of these models prioritize patient safety and reduce healthcare costs by reducing costly and avoidable trips to the hospital,â the statement said. ET3 is also available for Empire Medicaid members.
“We are on a mission to materially and measurably improve the health of all New Yorkers, and we know that over the past year people have become more open to receiving care in a variety of ways, including home, âsaid Jordan Vidor, Empire BlueCross’s regional vice president, BlueShield, Supplier Solutions, noted.
Empire is also a participating provider in the Mount Sinai Visiting Doctors Program, an integrated model of care focused on homebound members with chronic illnesses, providing a dedicated team working together to meet the clinical and social needs of primary and palliative care.
Additionally, the new agreement details a plan for Mount Sinai and Empire to improve two-way data, as part of Empire’s goal of having 80% of its members logged in with admission, discharge notifications. and real-time transfer and better integration of clinical information by the end of 2022.